Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
NovaBay Pharmaceuticals, Inc. (NBY) had Income from Continuous Operations of $-9.64M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$14.73M |
|
$-16.70M |
|
$6.83M |
|
$7.89M |
|
$22.32M |
|
$-7.60M |
|
$-2.04M |
|
$-9.64M |
|
$-9.64M |
|
$-9.64M |
|
|
Income from Continuous Operations |
$-9.64M |
$-9.64M |
|
$-9.64M |
|
$-7.60M |
|
$-3.11M |
|
4.21M |
|
4.21M |
|
$-3.96 |
|
$-3.96 |
|
| Balance Sheet Financials | |
$7.15M |
|
$0.09M |
|
$1.88M |
|
$9.03M |
|
$4.28M |
|
-- |
|
$1.44M |
|
$5.72M |
|
$1.36M |
|
$3.31M |
|
$3.31M |
|
11.23M |
|
| Cash Flow Statement Financials | |
$-4.13M |
|
$-0.02M |
|
$1.91M |
|
$5.85M |
|
$3.61M |
|
$-2.24M |
|
$0.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.67 |
|
-- |
|
-- |
|
-- |
|
0.34 |
|
53.61% |
|
-51.58% |
|
-51.58% |
|
-21.12% |
|
-65.46% |
|
-113.38% |
|
$-4.15M |
|
-- |
|
-- |
|
-- |
|
1.63 |
|
2.37 |
|
19.40 |
|
18.81 |
|
-706.75% |
|
-290.89% |
|
-106.71% |
|
-290.89% |
|
$0.30 |
|
$-0.98 |
|
$-0.98 |
|